Immune-mediated respiratory adverse events of checkpoint inhibitors

Current Opinion in Oncology

Volumn 28, Issue 4, 2016, Pages 269-277

  Tabchi, Samer ^a   Messier, Christine ^a   Blais, Normand ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

anti CTLA 4; anti PD 1; anti PD L1; checkpoint inhibitors; immune mediated pneumonitis; immunotherapy; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASE; REVIEW; CHEMICALLY INDUCED; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; PNEUMONIA;

EID: 84965045436     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000291     Document Type: Review

References (44)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (London, England) 2001; 357:539-545.
2. Ribas A. Releasing the brakes on cancer immunotherapy. New Engl J Med 2015; 373:1490-1492.
3. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY) 1996; 271:1734-1736.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363:711-723.
5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364:2517-2526.
6. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Annals Pharmacotherapy 2015; 49:907-937.
7. Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014; 74:1993-2013.
8. Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in nonsmall cell lung cancer. Am Soc Clin Oncol 2013.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.
10. Berthod G, Lazor R, Letovanec I, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012; 30:e156-e159.
11. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-268.
12. Xiao Y, Yu S, Zhu B, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 2014; 211:943-959.
13. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56.
14. Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012; 2012.
15. Nishino M, Sholl LM, Hatabu H, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. New Engl J Med 2015; 373:288-290.
16. Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immunerelated adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015; 3:1185-1192.
17. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-622.
18. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15:700-712.
19. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113:1581-1588.
20. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med 2015; 373:23-34.
21. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Engl J Med 2015; 372:2006-2017.
22. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012; 366:2443-2454.
23. Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced nonsmall-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO Meeting Abstracts 2014; 32 (15-suppl):8112.
24. Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with nonsmall cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32 (15-suppl):8020.
25. Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO Meeting Abstracts 2014; 32 (18-suppl):LBA9000.
26. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-1030.
27. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. New Engl J Med 2015; 372:2018-2028.
28. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med 2015; 373:1803-1813.
29. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigatorchoice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16:908-918.
30. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med 2013; 369: 134-144.
31. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med 2015; 373:1627-1639.
32. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl J Med 2015; 373:123-135.
33. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 2015.
34. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med 2015; 372:320-330.
35. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med 2015; 372:2521-2532.
36. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
37. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012; 366:2455-2465.
38. Powles T, Vogelzang N, Fine G, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncology 2014; 32 (15 Suppl):128960-129144.
39. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multiarm expansion study ofMEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014; 32 (15 Suppl):134136-134144.
40. Rizvi NA, Brahmer JR, Ou S-HI, et al., editors. Safety and clinical activity of MEDI4736, an antiprogrammed cell death-ligand 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings; 2015.
41. Besse B, Johnson M, Jaenne P, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected nonsmall cell lung cancer (NSCLC). Eur J Cancer 2015.
42. Vansteenkiste J, Fehrenbacher L, Spira A, et al. Atezolizumab monotherapy vs docetaxel in 2L/3L nonsmall cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Eur J Cancer 2015.
43. US National Institutes of Health, Bethesda, MD. Common Terminology for clinical adverse events version 4. 03. Respiratory, thoracic and mediastinal disorders; 14 June 2010. http://evs. nci. nih. gov/ftp1/CTCAE/CTCAE-4. 03-2010-06-14-QuickReference-8. 5x11. pdf.
44. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96-128.